Molecular drivers of cellular metabolic reprogramming in melanoma

Trends in Molecular Medicine

Volumn 21, Issue 3, 2015, Pages 164-171

  Abildgaard, Cecilie ^a   Guldberg, Per ^a  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

Author keywords

BRAF; Melanoma; Metabolism; Mitochondria; Oncogene

Indexed keywords

ARF PROTEIN; B RAF KINASE; GLUCOSE; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; ANTINEOPLASTIC AGENT;

BIOENERGY; CELL METABOLISM; HUMAN; MELANOMA; MELANOMA CELL; NUCLEAR REPROGRAMMING; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; GENETICS; METABOLISM; MITOCHONDRION; PATHOLOGY; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELLULAR REPROGRAMMING; HUMANS; MELANOMA; MITOCHONDRIA; PROTO-ONCOGENE PROTEINS B-RAF; SIGNAL TRANSDUCTION;

EID: 84924569931     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2014.12.007     Document Type: Review

References (81)

1. Miller A.J., Mihm M.C. Melanoma. N. Engl. J. Med. 2006, 355:51-65.
2. Shtivelman E., et al. Pathways and therapeutic targets in melanoma. Oncotarget 2014, 5:1701-1752.
3. Tsao H., et al. Melanoma: from mutations to medicine. Genes Dev. 2012, 26:1131-1155.
4. Griewank K.G., et al. Genetic alterations and personalized medicine in melanoma: progress and future prospects. J. Natl. Cancer Inst. 2014, 106:djt435.
5. Berger M.F., et al. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 2012, 485:502-506.
6. Hodis E., et al. A landscape of driver mutations in melanoma. Cell 2012, 150:251-263.
7. Krauthammer M., et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat. Genet. 2012, 44:1006-1014.
8. Nikolaev S.I., et al. Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat. Genet. 2012, 44:133-139.
9. Stark M.S., et al. Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing. Nat. Genet. 2012, 44:165-169.
10. Davies H., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
11. Albino A.P., et al. Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype. Oncogene 1989, 4:1363-1374.
12. Curtin J.A., et al. Somatic activation of KIT in distinct subtypes of melanoma. J. Clin. Oncol. 2006, 24:4340-4346.
13. Van Raamsdonk C.D., et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 2009, 457:599-602.
14. Van Raamsdonk C.D., et al. Mutations in GNA11 in uveal melanoma. N. Engl. J. Med. 2010, 363:2191-2199.
15. Michaloglou C., et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005, 436:720-724.
16. Pollock P.M., et al. High frequency of BRAF mutations in nevi. Nat. Genet. 2003, 33:19-20.
17. Vredeveld L.C., et al. Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. Genes Dev. 2012, 26:1055-1069.
18. Mooi W.J., Peeper D.S. Oncogene-induced cell senescence - halting on the road to cancer. N. Engl. J. Med. 2006, 355:1037-1046.
19. Lee A.C., et al. Ras proteins induce senescence by altering the intracellular levels of reactive oxygen species. J. Biol. Chem. 1999, 274:7936-7940.
20. Serrano M., et al. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997, 88:593-602.
21. Meyle K.D., Guldberg P. Genetic risk factors for melanoma. Hum. Genet. 2009, 126:499-510.
22. Bartkova J., et al. The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res. 1996, 56:5475-5483.
23. Dahl C., et al. Mutual exclusivity analysis of genetic and epigenetic drivers in melanoma identifies a link between p14 ARF and RARbeta signaling. Mol. Cancer Res. 2013, 11:1166-1178.
24. Christensen C., et al. A short acidic motif in ARF guards against mitochondrial dysfunction and melanoma susceptibility. Nat. Commun. 2014, 5:5348.
25. Sviderskaya E.V., et al. p16/cyclin-dependent kinase inhibitor 2A deficiency in human melanocyte senescence, apoptosis, and immortalization: possible implications for melanoma progression. J. Natl. Cancer Inst. 2003, 95:723-732.
26. Guldberg P., et al. Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res. 1997, 57:3660-3663.
27. Tsao H., et al. Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines. Oncogene 1998, 16:3397-3402.
28. Tsao H., et al. Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines. Cancer Res. 2000, 60:1800-1804.
29. Davies M.A., et al. A novel AKT3 mutation in melanoma tumours and cell lines. Br. J. Cancer 2008, 99:1265-1268.
30. Omholt K., et al. Mutations of PIK3CA are rare in cutaneous melanoma. Melanoma Res. 2006, 16:197-200.
31. Stahl J.M., et al. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res. 2004, 64:7002-7010.
32. Silva J.M., et al. BRAFV600E cooperates with PI3K signaling, independent of AKT, to regulate melanoma cell proliferation. Mol. Cancer Res. 2014, 12:447-463.
33. Tsao H., et al. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J. Invest. Dermatol. 2004, 122:337-341.
34. Warburg O., et al. The metabolism of tumors in the body. J. Gen. Physiol. 1927, 8:519-530.
35. Abildgaard C., et al. Bioenergetic modulation with dichloroacetate reduces the growth of melanoma cells and potentiates their response to BRAFV600E inhibition. J. Transl. Med. 2014, 12:247.
36. de Moura B., et al. Mitochondrial respiration - an important therapeutic target in melanoma. PLoS ONE 2012, 7:e40690.
37. Hall A., et al. Dysfunctional oxidative phosphorylation makes malignant melanoma cells addicted to glycolysis driven by the (V600E)BRAF oncogene. Oncotarget 2013, 4:584-599.
38. Scott D.A., et al. Comparative metabolic flux profiling of melanoma cell lines: beyond the Warburg effect. J. Biol. Chem. 2011, 286:42626-42634.
39. Kluza J., et al. Inactivation of the HIF-1alpha/PDK3 signaling axis drives melanoma toward mitochondrial oxidative metabolism and potentiates the therapeutic activity of pro-oxidants. Cancer Res. 2012, 72:5035-5047.
40. Parmenter T.J., et al. Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. Cancer Discov. 2014, 4:423-433.
41. Zeller K.I., et al. An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets. Genome Biol. 2003, 4:R69.
42. Morrish F., et al. Myc-dependent mitochondrial generation of acetyl-CoA contributes to fatty acid biosynthesis and histone acetylation during cell cycle entry. J. Biol. Chem. 2010, 285:36267-36274.
43. Haq R., et al. Oncogenic BRAF regulates oxidative metabolism via PGC1alpha and MITF. Cancer Cell 2013, 23:302-315.
44. Kumar S.M., et al. Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma. Cancer Res. 2007, 67:3177-3184.
45. Lim J.H., et al. Targeting mitochondrial oxidative metabolism in melanoma causes metabolic compensation through glucose and glutamine utilization. Cancer Res. 2014, 74:3535-3545.
46. Chau M.D., et al. Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK-SIRT1-PGC-1alpha pathway. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:12553-12558.
47. Huang B., et al. Adiponectin promotes pancreatic cancer progression by inhibiting apoptosis via the activation of AMPK/Sirt1/PGC-1alpha signaling. Oncotarget 2014, 5:4732-4745.
48. Kuphal S., et al. Constitutive HIF-1 activity in malignant melanoma. Eur. J. Cancer 2010, 46:1159-1169.
49. Mills C.N., et al. Expression and function of hypoxia inducible factor-1 alpha in human melanoma under non-hypoxic conditions. Mol. Cancer 2009, 8:104.
50. Vazquez F., et al. PGC1alpha expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress. Cancer Cell 2013, 23:287-301.
51. Zundel W., et al. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev. 2000, 14:391-396.
52. Widlund H.R., Fisher D.E. Microphthalamia-associated transcription factor: a critical regulator of pigment cell development and survival. Oncogene 2003, 22:3035-3041.
53. Feige E., et al. Hypoxia-induced transcriptional repression of the melanoma-associated oncogene MITF. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:E924-E933.
54. Garraway L.A., et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 2005, 436:117-122.
55. Bertolotto C., et al. A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature 2011, 480:94-98.
56. Yokoyama S., et al. A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature 2011, 480:99-103.
57. Esteve-Puig R., et al. Uncoupling of the LKB1-AMPKalpha energy sensor pathway by growth factors and oncogenic BRAF. PLoS ONE 2009, 4:e4771.
58. Zheng B., et al. Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Mol. Cell 2009, 33:237-247.
59. Blackman R.K., et al. Mitochondrial electron transport is the cellular target of the oncology drug elesclomol. PLoS ONE 2012, 7:e29798.
60. Ho J., et al. Importance of glycolysis and oxidative phosphorylation in advanced melanoma. Mol. Cancer 2012, 11:76.
61. Passos J.F., et al. Mitochondrial dysfunction accounts for the stochastic heterogeneity in telomere-dependent senescence. PLoS Biol. 2007, 5:e110.
62. Sharpless N.E. INK4a/ARF: a multifunctional tumor suppressor locus. Mutat. Res. 2005, 576:22-38.
63. Hauschild A., et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012, 380:358-365.
64. Sosman J.A., et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med. 2012, 366:707-714.
65. Flaherty K.T., et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N. Engl. J. Med. 2012, 367:107-114.
66. Flaherty K.T., et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 2012, 367:1694-1703.
67. Guo J., et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J. Clin. Oncol. 2011, 29:2904-2909.
68. Hodi F.S., et al. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J. Clin. Oncol. 2013, 31:3182-3190.
69. Niehr F., et al. Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations. J. Transl. Med. 2011, 9:76.
70. Yuan P., et al. Phenformin enhances the therapeutic benefit of BRAF(V600E) inhibition in melanoma. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:18226-18231.
71. Pollak M.N. Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov. 2012, 2:778-790.
72. Kaplon J., et al. A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. Nature 2013, 498:109-112.
73. Muthusamy V., et al. Amplification of CDK4 and MDM2 in malignant melanoma. Genes Chromosomes Cancer 2006, 45:447-454.
74. Jonsson G., et al. Genomic profiling of malignant melanoma using tiling-resolution arrayCGH. Oncogene 2007, 26:4738-4748.
75. Freedberg D.E., et al. Frequent p16-independent inactivation of p14ARF in human melanoma. J. Natl. Cancer Inst. 2008, 100:784-795.
76. Shoushtari A.N., Carvajal R.D. GNAQ and GNA11 mutations in uveal melanoma. Melanoma Res. 2014, 24:525-534.
77. Dahl C., et al. KIT is a frequent target for epigenetic silencing in cutaneous melanoma. J. Invest. Dermatol. 2015, 135:516-524.
78. Guldberg P., et al. Somatic mutation of the Peutz-Jeghers syndrome gene, LKB1/STK11, in malignant melanoma. Oncogene 1999, 18:1777-1780.
79. Rowan A., et al. Somatic mutations in the Peutz-Jeghers (LKB1/STKII) gene in sporadic malignant melanomas. J. Invest. Dermatol. 1999, 112:509-511.
80. Kraehn G.M., et al. Extra c-myc oncogene copies in high risk cutaneous malignant melanoma and melanoma metastases. Br. J. Cancer 2001, 84:72-79.
81. Mirmohammadsadegh A., et al. Epigenetic silencing of the PTEN gene in melanoma. Cancer Res. 2006, 66:6546-6552.